T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Top Cited Papers
- 11 November 2016
- journal article
- review article
- Published by Elsevier in Antiviral Research
- Vol. 137, 82-92
- https://doi.org/10.1016/j.antiviral.2016.11.006
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Identification of Residues of SARS-CoV nsp1 That Differentially Affect Inhibition of Gene Expression and Antiviral SignalingPLOS ONE, 2013
- Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoVVaccine, 2011
- A Comprehensive Comparison of Transmembrane Domains Reveals Organelle-Specific PropertiesCell, 2010
- A 219-mer CHO-Expressing Receptor-Binding Domain of SARS-CoV S Protein Induces Potent Immune Responses and Protective ImmunityViral Immunology, 2010
- Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infectionArchiv für die gesamte Virusforschung, 2009
- Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cellsBiochemical and Biophysical Research Communications, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVVaccine, 2007
- Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigenJournal of General Virology, 2007